Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for academic researchers and scientific institutions seeking to conduct fundamental research improving mammalian model systems for translational research purposes. The program supports R01-level research projects that develop, refine, or validate animal models to enhance their applicability in predicting human disease biology and therapeutic outcomes. Eligible applicants typically include universities, research hospitals, freestanding research institutions, and nonprofit research organizations with NIH institutional support. The funding supports hypothesis-driven research that advances the methodological and biological understanding of mammalian models, though clinical trials are explicitly not permitted under this mechanism. Geographic scope is national; researchers from all U.S. states and territories may apply.
Not the right fit? Find grants for your organization in 5 questions →
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients’ benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- SF-424 (R&R) form and face page with institutional signature
- Project Narrative (Research Strategy) describing aims, significance, innovation, and approach
- Detailed budget and budget justification for the entire project period
- Biographical sketches (NIH format) for all key personnel
- Letters of support from collaborating institutions if applicable
- Animal care and use protocol summary (IACUC approval required before funding)
- Data management and sharing plan
- Facilities and resources documentation
- Current and pending support disclosure for all senior personnel
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.393 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$213,206,023
-
$56,551,552
-
$48,640,472
-
$47,009,863
-
$42,878,192
-
$37,448,862
-
$29,324,004
-
$26,395,336
-
$24,427,436
-
$23,149,727
Top States by Funding
- MA 10 awards $374.4M
- CA 10 awards $260.1M
- MN 4 awards $106.9M
- NY 7 awards $99.9M
- TN 7 awards $97.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.393). How funding has trended year over year.
| 2024 | $754,945,159 | |
| 2025 | $834,514,512 | |
| 2026 est. | $520,096,276 |
FAQ
Who is eligible to apply for this R01 grant?
Domestic and foreign institutions (universities, hospitals, research centers, nonprofit organizations) with 501(c)(3) status or equivalent can apply. Principal investigators must hold a Ph.D., M.D., D.D.S., D.V.M., or equivalent research doctoral degree, though early-career researchers are encouraged.
What types of research projects are funded?
This program supports research to improve, develop, or validate mammalian model systems (mice, rats, primates, dogs, etc.) for translational research. Projects must focus on enhancing model applicability, not conducting clinical trials or direct patient studies.
What is the typical funding range and project duration?
R01 grants typically range from $250,000 to $500,000 annually depending on the project scope and complexity. Awards are generally for 4-5 year project periods, though the exact amount varies by NIH institute.
When is the application deadline and what is the review timeline?
The current deadline is September 7, 2026. Applications typically undergo two levels of NIH review (scientific review and program officer evaluation), with results usually available 3-4 months after the deadline.
Why might my application be competitive?
Strong applications clearly articulate the scientific gap, show how improved models will advance translational research, include strong preliminary data, have experienced teams, and demonstrate institutional commitment and resources.
💡 Tips for applicants
- Clearly articulate the specific limitations of existing mammalian models and precisely how your research addresses those gaps to improve translational applicability.
- Include robust preliminary data demonstrating feasibility and the scientific validity of your proposed model improvements or validations.
- Provide detailed comparative analysis showing how your enhanced model will better predict human biology, disease progression, or therapeutic response compared to standard models.
- Use the NIH Biosketch and Research Strategy sections to establish your team's track record in animal model development and translational research collaborations.
- Ensure your budget narrative justifies all costs, particularly for animal care, veterinary oversight, and model characterization studies, as reviewers scrutinize these carefully.
⚠️ Common mistakes
Applications often fail because they focus too narrowly on basic animal model optimization without clearly connecting to translational research impact or human disease relevance. Many applicants underestimate the detail required in describing model validation protocols and comparative studies. Additionally, proposals that hint at clinical trial components or direct clinical applications risk rejection under this mechanism, which explicitly excludes clinical trial research.
Similar grants
- OPEN Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health